Newsroom
Sorted by: Latest
-
Diabetology、経口GLP-1製剤「Oraglutide™」の画期的な臨床データを発表
ニューオーリンズ--(BUSINESS WIRE)--(ビジネスワイヤ) -- Diabetology Limited(ジャージー島)は、ニューオーリンズで開催の米国糖尿病学会(ADA)第86回年次学術集会におけるポスター発表1724-P(https://diabetology.co.uk/ada-poster)で、Oraglutide™に関する初のヒトデータを報告しています。Oraglutide™は、独自の「Axcess™」送達技術を用いて製剤化された、腸管内で放出される小型カプセル型の経口セマグルチド製剤です。 主なポイント 6日間の血糖コントロール:Oraglutide™ 4 mgを単回経口投与したところ、血糖値は持続的に低下し、6日目にも14%の低下が認められました(p=.046)。この6日間という効果持続期間は、ヒトを対象とした静脈内ブドウ糖負荷試験(IVGTT)において、経口GLP-1製剤を単回投与した際にこれまでに報告された中で最長です。 インスリン分泌が28%増加:プラセボと比較して、インスリンAUC(%)は投与日(0日目)に12%(p=0.02)、1日目に28%(p...
-
Samenvatting: Diabetology’s baanbrekende klinische gegevens van Oraglutide™ Oral GLP-1
NEW ORLEANS--(BUSINESS WIRE)--Posterpresentatie van Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P tijdens de ADA 86e Scientific Session, New Orleans, rapporteert de eerste menselijke gegevens van Oraglutide™ — klein pilletje in de darm vrijkomende orale semaglutide, samengesteld aan de hand van de eigen Axcess™-afgiftetechnologie. BELANGRIJKSTE HOOGTPUNTEN 6-daagse glucosecontrole: één enkele orale dosis van 4 mg Oraglutide™ produceerde een aanhoudende glucoseverlag...
-
Riassunto: I dati clinici innovativi di Diabetology su Oraglutide™ Oral GLP-1
NEW ORLEANS--(BUSINESS WIRE)--La presentazione poster di Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P alla 86a Sessione scientifica dell'ADA, a New Orleans, ha illustrato i primi dati umani su Oraglutide™, una piccola capsula di semaglutide orale rilasciata a livello intestinale, formulata utilizzando la tecnologia di rilascio proprietaria Axcess™. PUNTI SALIENTI Controllo del glucosio in 6 giorni: un'unica dose orale da 4 mg di Oraglutide™ ha prodotto una riduzion...
-
Dados clínicos inovadores da Diabetology com Oraglutide™, GLP-1 oral
NOVA ORLEANS--(BUSINESS WIRE)--Diabetology Limited (Jersey) (https://diabetology.co.uk/ada-poster) 1724-P na 86ª Sessão Científica da ADA, em Nova Orleans, relatando os primeiros dados em humanos do Oraglutide™ — semaglutida oral de liberação intestinal em pequenas cápsulas, formulada com a tecnologia proprietária de administração Axcess™. PRINCIPAIS DESTAQUES Controle glicêmico por 6 dias: Uma única dose oral de 4 mg de Oraglutide™ produziu uma queda sustentada na glicose. Medindo 14% no 6º di...
-
WhiteHawk Minerals Announces Pricing of Upsized Initial Public Offering
PHILADELPHIA--(BUSINESS WIRE)--WhiteHawk Income Corporation (“WhiteHawk Minerals” or the “Company”) today announced the pricing of the upsized initial public offering of 7,700,000 shares of its Class A common stock at a price to the public of $26.00 per share. The 7,700,000 share offering represents a 775,000 share upsize to the originally proposed 6,925,000 share offering. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 shares of its Class A c...
-
Datos clínicos revolucionarios de Diabetology sobre Oraglutide™ GLP-1 oral
NUEVA ORLEANS--(BUSINESS WIRE)--Presentación de Diabetology Limited (Jersey) de póster 1724-P (https://diabetology.co.uk/ada-poster) en la 86.ª Sesión Científica de la American Diabetes Association (ADA), celebrada en Nueva Orleans, con los primeros datos en humanos de Oraglutide™, una semaglutida oral de liberación intestinal en cápsulas pequeñas, formulada con la tecnología de administración patentada Axcess™. ASPECTOS DESTACADOS Control de glucosa durante 6 días: una dosis oral única de 4 mg...
-
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Clas...
-
Riassunto: Resident Evil Veronica debutterà nel 2027!
OSAKA, Giappone--(BUSINESS WIRE)--Capcom Co., Ltd. (TOKYO:9697) oggi ha annunciato che il lancio di Resident Evil Veronica, l'ultimo titolo nella serie Resident Evil, è previsto per il 2027. La saga Resident Evil comprende giochi di sopravvivenza in contesti di orrore, nei quali i giocatori si servono di una varietà di armi e altri oggetti per sopravvivere in situazioni terrificanti. Grazie a una base di appassionati giocatori a livello globale, le vendite complessive dei giochi fin dal primo t...
-
INVESTOR ALERT: Securities Class Action Filed Against Verra Mobility Corporation – Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Verra Mobility Corporation (“Verra Mobility” or the “Company”) (NASDAQ:VRRM) securities during the period of February 24, 2026 through May 26, 2026, inclusive (“the Class Period”).If you suffered a loss on your Verra Mobility investments, you have until August 4, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff ap...
-
PointsBet Goes All In on Grafana Cloud to Power AI-Driven Observability at Scale
SYDNEY--(BUSINESS WIRE)--Grafana Labs, the company behind the open observability cloud, today announced that PointsBet, one of Australia’s fastest-growing digital wagering operators, has selected Grafana Cloud as its unified observability platform. PointsBet is using Grafana Cloud to consolidate telemetry across its proprietary betting platform, accelerate incident resolution with AI-powered insights, and give engineering teams the visibility they need to own and operate their services with con...